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Sir,
We read with great interest two recent publications dealing
with the same topic, i.e. the public health risk related to the occur-
rence of acquired carbapenemase-producing Gram-negative spe-
cies in the animal world and the environment.1,2 Woodford et al.1
highlight the series of reports of carbapenemases found either
in bacteria isolated from non-human sources or in Salmonella
enterica subsp. enterica, a zoonotic species. This raises concern
about the real spread of these threatening organisms in the food
chain and other non-human sources of infection. Abraham et al.2
focus on the possible role of companion animals as a source of
carbapenemase-producing strains in humans, building their
hypotheses on two studies reporting NDM-1-producing Escherichia
coli isolates from dogs in the USA, and OXA-48-producing E. coli
and Klebsiella pneumoniae isolates, also from dogs, in Germany.
Both reports encourage public health authorities to implement mea-
sures to better evaluate the spread of carbapenemase-producing
strains in animals, and reinforce efforts leading to a reduction of anti-
biotic consumption in veterinary practice.
We fully agree that the implementation of surveillance studies
aimed to better evaluate and trace multidrug resistance in
general, and carbapenem resistance in particular, is crucial in the
fight against antibiotic resistance. We also agree that any effort
towards a reduction of antibiotic consumption is valuable and
must be sustained. However, we believe that the spread of
carbapenemase-producing isolates among animals is not the
main explanation for their occurrence in humans. Carbapenems
are not registered for use in veterinary medicine, even though they
may be used in specific circumstances in companion animals or
horses when dealing with multidrug-resistant Enterobacteriaceae.
This usage,at least in developed countries, remains rare.3 The occur-
rence of carbapenemase-producing isolates in companion animals,
as for extended-spectrum b-lactamase (ESBL) producers,4 most
probably results from contamination from the animal keeper, who
is statistically more exposed to broad-spectrum antibiotics, and
in particular to broad-spectrum b-lactams, than the animal
itself. In this regard, an increasing and irresponsible use of carbape-
nems in companion animals might contribute to the selection and
dissemination of carbapenem-resistant strains, and all efforts to
avoid carbapenem use in veterinary practice should be pursued.3
The real threat related to carbapenemase resistance in
humans comes from two main facts. The first corresponds to
the increased consumption of carbapenems worldwide, as a con-
sequence of an increased rate of resistance to broad-spectrum
cephalosporins among human isolates. Therefore, carbapenems,
although being last-resort antibiotics, are now considered to be
first-line therapeutic options in certain geographical areas where
multidrug resistance is endemic. The second main explanation
comes from the overall increase in human population movements
worldwide, including migration and tourism.5
In humans, carbapenemase-producing Enterobacteriaceae
may be either hospital acquired (mostly K. pneumoniae), or com-
munity acquired (mostly E. coli), either as colonizers or infectious
agents. Carbapenemase-producing E. coli are mainly the source of
community-acquired infections or colonization.5 Of note, E. coli,
by contrast with K. pneumoniae, may be identified in the food
chain. Numerous studies have been conducted over the past dec-
ade to evaluate the possible link between the occurrence of ESBL
producers among food-producing animals on one hand, and in
humans on the other. Despite the fact that the rate of colonization
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of animals (poultry, pigs, cattle etc.) is high, there is still little evi-
dence that ESBL producers are spreading mainly through the food
chain.4 Taking into account the paucity of reports of carbapenemase
producers in animals, and the fact that carbapenems are not used in
food-producing animals, the risk to public health remains marginal.
Nowadays, the major threat related to the spread of carbape-
nemase producers among humans is linked to a lack of hygiene,
to contaminated drinking water and to poor control of antibiotic
usage in some highly populated geographical areas.5 As a conse-
quence, some countries may become endemic not only for ESBL
producers but also for carbapenemase producers. As examples, it
is estimated that among isolates associated with intra-abdominal
infections in India during 2008, 61% and 47% were ESBL-
producing E. coli and K. pneumoniae, respectively.6 In Pakistan,
the faecal carriage of NDM-1-producing isolates among hospita-
lized patients was estimated at 15%–20%.7
In a country such as Switzerland, where the rate of patient
colonization with ESBL-producing Enterobacteriaceae at admis-
sion has been evaluated to be 4%–5%,8 while being 8.4%
among the Swiss slaughter cattle population,9 recent surveys
have reported the lack of detection of carbapenemase-producing
Enterobacteriaceae among farm animals and community
patients.10,11 The first case of colonization by a carbapenemase-
producing S. enterica strain has recently been reported, being an
OXA-48 producer recovered from a patient transferred from Libya to
Switzerland.12 Knowing that Libya is endemic for OXA-48-producing
Enterobacteriaceae,13 this case further highlights that the risk of
acquisition of carbapenemase producers mainly comes from
human endemic areas.
Rapid identification of carbapenemase producers by using
easy-to-handle and affordable techniques will contribute to the
recognition of infected and colonized patients at an early
stage.14 This will allow the rapid implementation of isolation
and cohorting strategies, and the improvement of antibiotic stew-
ardship to prevent the development of outbreaks. It may also con-
tribute to better identification of the possible dissemination of
carbapenemase producers, not only within the human population
but also from a human source to animals.
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